In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
The FDA will now allow use of Prevnar 13 in children and adolescents ages 6 to 17, a recent expansion that could allow Pfizer to hit lofty sales goals.
Pfizer has always harbored substantial goals for its pneumococcal conjugate vaccine, and the pharma giant got a leg up Tuesday when the European Commission approved the use of Prevenar 13 in older children and adolescents.
The study of the shot, known as Prevnar in the U.S. and Prevenar in other countries and used to prevent infection by streptococcus pneumonia, showed the immune response to the vaccine in the 18- to 49-year-old age group was noninferior when compared to the response in the 60- to 64-year-old age group.
Prevnar 13 is the first and only pneumococcal vaccine to be granted WHO prequalification for adults.
Pfizer ($PFE) has pinned big hopes on Prevnar 13, the latest version of its vaccine against pneumococcus bacteria.
Pfizer ($PFE) has won a much-anticipated FDA approval for Prevnar 13 for older adults to prevent pneumonia and other diseases caused by 13 Streptococcus pneumoniae serotypes contained in the vaccine....
In a 14-1 vote, a panel of FDA experts say Pfizer's ($PFE) Prevnar 13 protected adults over 50 from pneumococcal infections, paving the way for a likely approval in January. Earlier this week agency
The FDA will take 90 more days to review Pfizer's request that Prevnar 13 be approved for adults 50 and over. Pfizer has submitted additional data gathered from two studies of the vaccine used in
The FDA has put off its decision on expanding the use of Pfizer's Prevnar 13 vaccine to adults 50 and older. A decision is now expected 90 days later in January 2012. Pfizer release | Report